MarciaSBroseMDPhD
Oncology • Philadelphia, PACancer Genetics/Cancer Risk Assessment, Endocrine Cancer, Head & Neck Cancer
Director Cancer Services and Vice Chair Medical Oncology, Jefferson Northeast - Sidney Kimmel Cancer Center, Co-Director Comminity Based Clinical Trials, Jefferson Medical College - Sidney Kimmel Cancer Center, Chief of Medical Oncology, Jefferson Torresdale Hospital, Philadelphia, PA
Dr. Brose is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Sidney Kimmel Cancer Center - Jefferson Torresdale Hospital
10800 Knights Rd, 3rd Floor
Philadelphia, PA 19104Phone+1 215-890-3030Fax+1 215-890-3031- Is this information wrong?
Summary
- Director of Cancer Services with focus on delivery of top-tier care in the community setting. Extensive clinical trial experience with leadership in clinical trials for advanced thyroid cancer and genetically targeted therapies in solid tumors. Global leader in the development of advanced thyroid cancer therapeutics, with experience lecturing and teaching on a global level.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1997 - 2000- University of Pennsylvania Health SystemResidency, Internal Medicine, 1995 - 1997
Weill Cornell MedicineClass of 1995
Certifications & Licensure
PA State Medical License 1996 - 2024- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Start of enrollment: 2006 Feb 01
- Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Start of enrollment: 2010 Nov 01
- Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Start of enrollment: 2015 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascul...Jaume Capdevila, Jolanta Krajewska, Jorge Hernando, Bruce Robinson, Steven I Sherman, Barbara Jarzab, Chia-Chi Lin, Fernanda Vaisman, Ana O Hoff, Erika Hitre, Daniel W...> ;Thyroid. 2024 Mar 1
- Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.Choe, J., Babajanyan, S., Gianoukakis, A., Bowles, D., Owonikoko, T., Worden, F., Wirth, L., Brose, M.> ;European Thyroid Journal. 2024 Feb 1
- 1 citationsEvaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.Makker, V., Taylor, M., Aghajanian, C., Cohn, A., Brose, M., Simone, C., Cao, Z., Suttner, L., Loboda, A., Cristescu, R., Jelinic, P., Orlowski, R., Dutta, L., Matsui,...> ;Journal for Immunotherapy of Cancer. 2024 Jan 19
- Join now to see all
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
- Targeted Oncogene Therapy Before Surgery in Pediatric Patients with Advanced Invasive Thyroid Cancer at Initial PresentationKen Kazahaya, Kara K Prickett, Sanjay R Parikh, Marcia S Brose, JAMA Otolaryngology–Head & Neck Surgery
Lectures
- A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer ...2019 ASCO Annual Meeting - 6/1/2019
- A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptoma...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Targeted Oncogene Therapy Before Surgery in Pediatric Patients with Advanced Invasive Thyroid Cancer at Initial PresentationJuly 2020
- Join now to see all
Press Mentions
Thyroid Cancer Specialist Joins Sidney Kimmel Cancer Center at JeffersonOctober 22nd, 2021- Exelixis Announces U.S. FDA Approval of CABOMETYX® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerSeptember 17th, 2021
- Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021June 7th, 2021
- Join now to see all
Grant Support
- BRCA1 Deletion In Murine Cells And Mammary TissueNational Cancer Institute2003–2007
Professional Memberships
- Member
Hospital Affiliations
Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
